NVIDIA launches a model that predicts how two proteins bind together
This is the slowest, priciest step in drug discovery: figuring out how a molecule locks onto its target before sinking millions into lab work. Novo Nordisk is already using it, which means this is moving out of the research stage and into a real pharma pipeline.
practitioners › Proteina-Complexa runs on the BioNeMo platform, backed by an open dataset of millions of predicted protein complex structures built with Google DeepMind, EMBL-EBI, and Seoul National University.
investor.nvidia.com →